Calithera Bio initiates phase 1 trial of arginase Inhibitor CB-280 for CF treatment
Calithera announced it has initiated a Phase 1 clinical trial with CB-280, a novel, orally dosed arginase inhibitor being developed for treatment of cystic fibrosis. The first-in-human Phase 1 trial will evaluate safety, tolerability and pharmacokinetic profile of oral CB-280 in healthy volunteers. February 21, 2019